All In Biotech

Drug Trial Radar · NCT06710431

A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder

A Double-blind, Placebo-controlled, Phase IIA Human Laboratory Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder

Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Oct 1, 2025

Primary completion

Jun 1, 2027

Study completion Dec 1, 2027

Sponsor

Lead sponsor
Afasci IncIndustry
Sponsor type
Industry
First posted
Nov 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and exploratory efficacy of AFA-281 in patients with Alcohol use disorder on cravings, subjective response to alcohol, pain thresholds, anxiety, depression, and sleep.

Conditions

  • Alcohol Abuse
  • Alcohol Abuse/addiction
  • Anxiety
  • Pain Threshold
  • Depression Disorders
  • Sleep Disorder

Interventions

  • AFA-281Drug

    AFA-281

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cue-induced alcohol cravingTime frame: predose and weekly through Week 4
  2. Stress-induced alcohol cravingTime frame: predose and weekly through Week 4
  3. Subjective response to alcoholTime frame: predose and weekly through Week 4
  4. Pain assessmentsTime frame: predose and weekly through Week 4
  5. Safety and tolerability assessmentTime frame: Predose and Daily

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.